Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Infinium PharmachemNSE:INFINIUM -1.12%90 EV-to-EBIT is 20.52 as of Sep. 21, 2026, which is 2% above its 10-year median of 20.15. GuruFocus rates NSE:INFINIUM with a GF Score™ of 90/100 and a GF Value™ of ₹312.42 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,291 Chemicals companies, Infinium Pharmachem ranks worse than 58.25% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Infinium Pharmachem's Enterprise Value for the quarter that ended in Mar. 2026 was ₹ Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Infinium Pharmachem's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹206 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Infinium Pharmachem EV-to-EBIT Related Terms
Infinium Pharmachem EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Infinium Pharmachem's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Infinium Pharmachem's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Infinium Pharmachem EV-to-EBIT vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Infinium Pharmachem's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Infinium Pharmachem's EV-to-EBIT falls into.
Infinium Pharmachem's current Enterprise Value is ₹4,237 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Infinium Pharmachem's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹206 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Infinium Pharmachem (NSE:INFINIUM) has a EV-to-EBIT of 20.52 as of Sep. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Infinium Pharmachem and its competitors. This is near median its historical median of 20.15. Over the past decade, Infinium Pharmachem's EV-to-EBIT has ranged from 8.88 to 32.78. According to the industry distribution chart, Infinium Pharmachem ranks #752 out of 1291 companies in the Chemicals industry, placing it in the top 58.2%.
Is Infinium Pharmachem's EV-to-EBIT too high?
Infinium Pharmachem's current EV-to-EBIT of 20.52 is near median its 10-year median of 20.15. Over the past 10 years, this metric has ranged from a low of 8.88 to a high of 32.78. The Chemicals industry median EV-to-EBIT is 16.66. Infinium Pharmachem's value of 20.52 is 23.2% above this industry median. Based on the distribution chart, Infinium Pharmachem ranks #752 out of 1291 companies in the Chemicals industry, which is below the industry midpoint. Overall, Infinium Pharmachem has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Infinium Pharmachem's EV-to-EBIT compare to DOW?
According to the Chemicals industry distribution chart, Infinium Pharmachem ranks #752 out of 1291 companies for EV-to-EBIT. This places Infinium Pharmachem in the lower half of its industry. The industry median EV-to-EBIT is 16.66. Infinium Pharmachem's value of 20.52 is 23.2% above this benchmark. Historically, Infinium Pharmachem's own EV-to-EBIT has ranged from 8.88 to 32.78 over the past decade. While the company's 10-year median is 20.15 vs. the industry median of 16.66, Infinium Pharmachem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Chemicals company?
The median EV-to-EBIT among Chemicals companies is 16.66, based on 1,291 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Infinium Pharmachem's current EV-to-EBIT of 20.52 is 23.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Infinium Pharmachem and its competitors. For the Chemicals industry, the median EV-to-EBIT is 16.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Infinium Pharmachem's current EV-to-EBIT is 20.52, which is near median its own 10-year median of 20.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infinium Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Infinium Pharmachem (NSE:INFINIUM) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹312.42, compared to a current price of ₹265.00 — trading 15.2% below its estimated fair value. The current EV-to-EBIT is 20.52, which is near median its 10-year median of 20.15 and 23.2% above the Chemicals industry median of 16.66. Infinium Pharmachem's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Infinium Pharmachem (NSE:INFINIUM), the current EV-to-EBIT is 20.52 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Infinium Pharmachem (NSE:INFINIUM) Overvalued in 2026?
Based on GuruFocus' analysis, Infinium Pharmachem stock appears to be undervalued.
The current stock price of ₹265.00 is trading 15.2% below its estimated GF Value™ of ₹312.42.
GuruFocus considers Infinium Pharmachem to be Modestly Undervalued.
Key valuation signals for NSE:INFINIUM:
EV-to-EBIT: 20.52 (near median its 10-year median of 20.15)
GF Value™: ₹312.42 vs. price of ₹265.00 (15.2% below fair value)
Industry Position: 23.2% above the Chemicals median (#752 of 1291)
No single metric tells the full story. See the NSE:INFINIUM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Infinium Pharmachem Ltd is engaged in the business of manufacturing and supplying Iodine, Iodine Derivatives and Active Pharmaceutical Ingredients (APIs). It provides fully integrated customized services from R & D to Commercial scale manufacturing and packaging for its products to the Pharmaceutical, Agrochemical, Nutraceutical, Speciality Chemicals and various other chemicals Industries.
90GF Score
Get the complete analysis for NSE:INFINIUM
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INFINIUM has been successfully added to your 
